Clinical trial
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent…
NCT00060632 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00060632 |
|---|---|
| Title | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) |
| Official title | A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Ariad Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Lymphoma, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | ridaforolimus |
| Enrollment | 46 |
| Start date | Apr 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | May 12, 2003 |
| Last update posted | Aug 27, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: